相关实验视频

Updated: Sep 15, 2025

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

负担能力问题和需要在印度的炎症性肠道疾病的先进治疗的报销过程

Nagesh Kamat¹, Gaurav Patil¹, Ankit Dalal¹

¹Institute of Gastrosciences, Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India.

Current medical research and opinion

|July 17, 2025

概括

炎症性肠病 (IBD) 治疗成本高,这是由于生物制剂. 印度的报销政策各不相同,使得许多人无法负担IBD护理费用,需要改变政策.

科学领域:

胃肠病学胃肠病学
卫生经济学卫生经济学
卫生政策卫生政策

背景情况:

炎症性肠病 (IBD),包括克罗恩氏病和性结肠炎,对于中度至重度的病例需要昂贵的生物疗法.
治疗费用已经从住院转向生物药物,印度的保险赔偿金变化很大,而且往往不足.
患者面临通过自扣,共同付款和共同保险的大量自付费用,这会影响负担能力.

研究的目的:

审查印度生物治疗成本和炎症性肠病 (IBD) 补偿的现状.
分析保险,生物仿制药和新兴疗法对IBD治疗负担能力的影响.
通过考虑付款人和制造商的观点,提出改善患者获取和结果的策略.

主要方法:

对当前IBD治疗成本的文献综述,重点关注印度的生物疗法和相关的报销政策.
对生物注射与注射的保险覆盖范围变化的分析.
检查生物类似药的经济影响和小分子和新型定价模型的潜力.

主要成果:

一些保险公司提供日托保险,而注射需要24小时入院,导致患者退款不一致.
生物仿制药降低了抗TNF成本,但并没有显著降低整体治疗费用.
尽管部分保险覆盖,但实质性的患者成本共享使得IBD医疗保健对许多人来说不可负担.

结论:

目前的报销政策和患者成本共享模式在印度为IBD生物疗法制造了重大财务障碍.
制造商必须使定价与付款人的观点保持一致,需要改变政策以提高可负担性.
采用小分子和全民健康覆盖,可能与生物制品的抵押贷款模式,可以提高患者的获取和结果.

关键词:

炎症性肠病是一种炎症性肠病.生物学的生物学.生物类似药物生物类似药物挑战挑战挑战挑战挑战药物费用药物费用药物费用

更多相关视频

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

相关概念视频

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...